Global Non-Alcoholic Steatohepatitis Biomarkers Market Size, Share, Growth Analysis Report - Forecast 2034

Non-Alcoholic Steatohepatitis Biomarkers Market: Industry Perspective

The global non-alcoholic steatohepatitis biomarkers market size was worth around USD 1.51 Billion in 2024 and is predicted to grow to around USD 13.18 Billion by 2034 with a compound annual growth rate (CAGR) of roughly 24.16% between 2025 and 2034. The report analyzes the global non-alcoholic steatohepatitis biomarkers market's drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the non-alcoholic steatohepatitis biomarkers industry.

Request Free Sample

Non-Alcoholic Steatohepatitis Biomarkers Market:

Non-alcoholic fatty liver disease (NAFLD), which develops when an excessive amount of fat builds up in the liver and causes inflammation & damage that results in liver scarring, progresses to non-alcoholic steatohepatitis (NASH). A biomarker is an indication for assessing both pathogenic and normal biological processes in the body and is considered the most accurate diagnostic tool for determining biological conditions. Noninvasive technologies are referred to as biomarker tools used to diagnose NASH conditions. The reviewed market is expanding as a result of the rising prevalence of metabolic comorbidities and NASH in the general population.

In addition, increased awareness of non-alcoholic fatty liver disease would open up new opportunities for the global non-alcoholic steatohepatitis biomarkers market size over the anticipated period. NAFLD can be correctly diagnosed using imaging techniques such as computed tomography, magnetic resonance imaging, and ultrasound scanning. These methods, however, are ineffective for detecting liver fibrosis or NASH. In the upcoming years, it is projected that these factors will increase demand for noninvasive diagnostic tools, such as serum biomarkers, for disease detection, thereby fueling the growth of the non-alcoholic steatohepatitis biomarkers market share. A surge in projects to create NASH medications creates a solid foundation for market expansion. The development of the global non-alcoholic steatohepatitis biomarkers market is being constrained by the adverse effects of NASH therapies as well as the absence of sophisticated diagnostic testing for NAFLD.

Key Insights

• As per the analysis shared by our research analyst, the global non-alcoholic steatohepatitis biomarkers market is estimated to grow annually at a CAGR of around 24.16% over the forecast period (2025-2034).
• Regarding revenue, the global non-alcoholic steatohepatitis biomarkers market size was valued at around USD 1.51 Billion in 2024 and is projected to reach USD 13.18 Billion by 2034.
• The non-alcoholic steatohepatitis biomarkers market is projected to grow at a significant rate due to rising global prevalence of NASH and associated liver diseases due to increasing rates of obesity and metabolic disorders, the growing demand for non-invasive diagnostic tools for early detection and monitoring, and ongoing advancements in biomarker identification and validation technologies.
• Based on Type, the Hepatic Fibrosis Biomarkers segment is expected to lead the global market.
• On the basis of End-User, the Research Institutes and Academics segment is growing at a high rate and will continue to dominate the global market.
• Based on region, North America is predicted to dominate the global market during the forecast period.

Non-Alcoholic Steatohepatitis Biomarkers Market: Growth Drivers

Increase in NAFLD and NASH prevalence is predicted to drive global market

Non-alcoholic liver illnesses are now occurring with greater frequency. NAFLD and other liver disorders are more common in patients with obesity and type 2 diabetes. The prevalence of liver illnesses not caused by alcohol is predicted to rise. It is projected that rising pollution levels and lifestyle changes will increase the prevalence of non-alcoholic liver disorders. Consequently, this will fuel the market for non-alcoholic steatohepatitis biomarkers.

Non-Alcoholic Steatohepatitis Biomarkers Market: Restraints

Lack of professionals and high infrastructure requirements is restraining the market growth

The lack of professionals is a major factor that is expected to limit the growth for the global non-alcoholic steatohepatitis biomarkers market Segmentation . The high cost of imaging testing is another issue that restrains market expansion. The analysis period's expansion of the global market may be constrained by the requirement for substantial expenditure on drug development. In addition, strict government regulations by the U.S. Food and Drug Administration (FDA) and the Medicines and Healthcare Products Regulatory Agency (MHRA), as well as the side effects connected with medications, are some of the factors impeding the growth of the global non-alcoholic steatohepatitis biomarkers market.

Non-Alcoholic Steatohepatitis Biomarkers Market: Segmentation Analysis

The global non-alcoholic steatohepatitis biomarkers market is segmented based on Type, End-User, and region.

Based on Type, the global non-alcoholic steatohepatitis biomarkers market is divided into Hepatic Fibrosis Biomarkers, Serum Biomarkers, Oxidative Stress Biomarkers, Apoptosis Biomarke, Others.

On the basis of End-User, the global non-alcoholic steatohepatitis biomarkers market is bifurcated into Research Institutes and Academics, Diagnostic Centres, Pharmaceutical Companies and CROs, Hospitals and Clinics, Others.

Non-Alcoholic Steatohepatitis Biomarkers Market: Report Scope

Non-Alcoholic Steatohepatitis Biomarkers Market: Regional Analysis

North America dominated the non-alcoholic steatohepatitis biomarkers market in 2021

The market for non-alcoholic steatohepatitis biomarkers is expanding in North America due to causes, including supportive government policies, increased incidence of infectious disorders, cardiovascular conditions, and diabetes. Research and development funding for non-alcoholic steatohepatitis biomarkers is strong, which supports medication development efforts and fosters industry expansion. Additionally, U.S. government rules encourage research into the creation of innovative compounds, which is expected to spur industrial expansion. In this area, it is predicted that the NASH biomarkers market will grow at a profitable CAGR.

Non-Alcoholic Steatohepatitis Biomarkers Market: Competitive Analysis

The report provides a company market share analysis to give a broader overview of the key market players. In addition, the report also covers key strategic developments of the market, including acquisitions & mergers, new product launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the non-alcoholic steatohepatitis biomarkers market on a global and regional basis.

The global non-alcoholic steatohepatitis biomarkers market is dominated by players like:

• Perspectum Diagnostics Ltd.
• Shenzhen New Industries Biomedical Engineering Co Ltd
• One Way Liver SL
• BioPredictive
• Cisbio
• Celerion
• Enterome
• Echosens
• GENFIT
• NGM Biopharmaceuticals
• Laboratory Corporation of America Holdings
• Pacific Biomarkers
• Quest Diagnostics Ltd
• Prometheus Laboratories Inc
• Regulus Therapeutics Inc.
• Xeptagen SpA
• Boehringer Ingelheim GmbH Inc.
• Bristol-Myers Squibb
• AstraZeneca and Pfizer Inc

Global Non-Alcoholic Steatohepatitis Biomarkers Market is segmented as follows:

By Biomarker Type

• Serum Biomarkers
• Biomarker Panels
• Fibrosis Biomarkers
• Imaging Biomarkers
• Others

By End-User

• Hospitals
• Diagnostic Centers
• Others

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa